Comparison of the efficacy and safety of Rituximab (MabtheraTM) and its biosimilar (RedituxTM) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis

Indian Journal of Medical and Paediatric Oncology

Volumn 34, Issue 4, 2013, Pages 292-298

  Roy, Partha Sarathi ^a   John, Shiji ^a   Karankal, Sadashiv ^a   Kannan, Sadhana ^a   Pawaskar, Preeti ^a   Gawande, Jayanta ^a   Bagal, Bhausaheb ^a   Khattry, Navin ^a   Sengar, Manju ^a   Menon, Hari ^a   Gujral, Sumeet ^a   Nair, Reena ^b  

^a TATA MEMORIAL HOSPITAL   (India)

^b Tata Medical Centre ^*  (India)

Author keywords

Anti CD20; Biosimilar; Lymphoid neoplasms; Monoclonal antibody; Observational study; Survival outcomes

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONGESTIVE CARDIOMYOPATHY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HERPES ZOSTER; HUMAN; INFUSION RELATED REACTION; INTESTINE PERFORATION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL RECORD REVIEW; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; ORAL MUCOSITIS; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TUMOR RECURRENCE; URINARY TRACT INFECTION;

EID: 84893326421     PISSN: 09715851     EISSN: 09752129     Source Type: Journal    
DOI: 10.4103/0971-5851.125248     Document Type: Review

References (11)

1. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-26.
2. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7.
3. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.
4. Biswas G, Parikh PM, Nair R, Bhagwat R, Bakshi A, Prabhash K, et al. Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience. J Assoc Physicians India 2006;54:29-33.
5. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: What clinicians should know. Blood 2012;120:5111-7.
6. Minghetti P, Rocco P, Cilurzo F, Vecchio LD, Locatelli F. The regulatory framework of biosimilars in the European Union. Drug Discov Today 2012;17:63-70.
7. Harris RJ. Heterogeneity of recombinant antibodies: Linking structure to function state of the art analytical methods for characterization of biological products and assessment of comparability. Karger 2005;122:117-27.
8. Kamoda S, Ishikawa R, Kakehi K. Capillary electrophoresis with laser-induced fluorescence detection for detailed studies on N-linked oligosaccharide profile of therapeutic recombinant monoclonal antibodies. J Chromatogr A 2006;1133:332-9.
9. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
10. Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res 2011;3:29-36.
11. Vallabhajosyula S, Baijal G, Vadhiraja BM, Fernandes DJ, Vidyasagar MS. Non-Hodgkin's lymphoma: Is India ready to incorporate recent advances in day to day practice? J Cancer Res Ther 2010;6:36-40.